Abstract
The newly recognized class of 5-hydroxytryptamine receptors (5HT3) may be involved in the induction of nausea, since their pharmacological antagonists are effective against emesis induced by chemotherapy. 5HT3 receptors are present on enteric neurons, and 5HT3 blockers may produce mild constipation; we thus hypothesized that 5HT3 receptors would modulate colonic motility. To determine if GR 38032F, a selective 5HT3 antagonist known to have antiemetic effects, influences colonic transit in health, a randomized, double-blind, placebo-controlled crossover study was performed. Using a radiopaque marker technique, colonic transit was quantified in 39 healthy volunteers (19 men, 20 nonpregnant women) 18–70 years of age. On a standard 25-g fiber diet, 16 mg of GR 38032F was given orally thrice daily. Gastrointestinal peptides (peptide YY, human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, substance P) were also measured in plasma fasting and postprandially. Mean total colonic transit time on placebo was 27.8 hr, while on GR 38032F it was 39.1 hr (P<0.0005). Transit times through the left colon (P<0.0005) and rectosigmoid (P<0.05) were prolonged by the drug, but right colonic transit was not significantly altered. Transit times did not correlate with age or gender, but subjects with shorter transit times were significantly more affected than were those with longer transit times. The peak release of peptide YY was minimally decreased following GR 38032F (P<0.01), but the peak and integrated postprandial responses of human pancreatic polypeptide, neurotensin, motilin, gastrin-cholecystokinin, and substance P were not significantly altered by the drug. We conclude that 5HT3 receptors may be involved in the regulation of colonic transit in healthy man.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rocha e Silva M, Valle JR, Picarelli ZP: A pharmacological analysis of the mode of action of serotonin (5-hydroxytryptamine) upon the guinea pig ileum. Br J Pharmacol 8:378–388, 1953
Gaddum JH, Picarelli ZP: Two kinds of tryptamine receptor. Br J Pharmcol 12:323–328, 1957
Peroutka SJ, Snyder SH: Multiple serotonin receptors: Differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16:687–699, 1979
Engel G, Hoyer P, Kalkmon HO, Wick MD: Pharmacological similarity between the 5HT-D-receptor on the guinea pig ileum and the 5HT2 binding site. Br J Pharmacol 84:106P, 1985
Kilpatrick GJ, Jones BJ, Tyers MB: Identification and distribution of 5HT3 receptors in rat brain using radioligand binding. Nature 330:746–748, 1987
Fozard JR, Mobarok A, Newgrosh G: Blockage of serotonin receptors on autonomic neurones by (−)-cocaine and some related compounds. Eur J Pharmacol 59:195–210, 1979
Richardson BP, Engel G, Donatsch P, Stadler PA: Identification of serotonin M-receptor subtypes and their specific blockage by a new class of drugs. Nature 316:126–131, 1986
Fozard JR: Neuronal 5-HT receptors in the periphery. Neuropharmacology 23:1473–1486, 1984
Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM: GR 38032F (GR-C507/75): A novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705, 1989
Jones BJ, Oakley NR, Tyers MB: The anxiolytic activity of GR 38032F, a 5HT3 receptor antagonist, in the rat and cynomolgus monkey. Br J Pharmacol 90:88p, 1987
Clinical Investigator's Brochure GR-C507/75: Glaxo Inc. North Carolina, 1988
Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG: Simplified assessment of segmental colonic transit. Gastroenterology 92:40–47, 1987
Chaussade S, Roche H, Khyara A, Couturier D, Guerre J: Mesure du temps de transit colique (TTC): description et validation d'une nouvelle technique. Gastroenterol Clin Biol 10:385–389, 1986
Fleiss JL. The Design and Analysis of Clinical Experiments. New York, Wiley, 1986, p 263
Meleagros L, Kreymann B, Ghatei MA, Bloom SR: Mouthto-cecum transit time in man is reduced by a novel serotonin M-receptor antagonist. Gut 28:A1373, 1987 (abstract)
Akkermans LMA, Vos A, Hoekstra A, Roelofs JMM, Horowitz M: Effect of ICS 205–930 (a specific 5HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 29:1249–1252, 1988
Roddy DR, Koch TR, Reilly WM, Carney JA, Go VLW: Identification and distribution of immunoreactive peptide YY in the human, canine, and murine gastrointestinal tracts: species-related antibody recognition differences. Regul Pept 18:201–212, 1987
Koch TR, Roddy DR, Go VLW: Abnormalities of fasting serum concentration of peptide YY in the idiopathic inflammatory bowel disease. Am J Gastroenterol 82:321–326, 1987
Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, Ciociola A: Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 34:1511–1515, 1989
Heitz Ph, Polak JM, Timson CM, Pearse AGE: Enterochromaffin cells as the endocrine source of gastrointestinal substance P. Histochemistry 49:343–347, 1976
Chan-Palay V, Jonsson G, Palay SL: Serotonin and substance P coexist in neurons of the rat's central nervous system. Proc Natl Acad Sci USA 75:1582–1586, 1978
Gore S, Gilmore IT, Haigh CG, Morris AI: Specific 5-hydroxytryptamine receptor (Type 3) antagonist GR 38032F slows colonic transit. Gut 30:A713, 1989 (abstract)
Author information
Authors and Affiliations
Additional information
Supported in part by a grant from Glaxo Group Research, Ltd., and the Mayo Digestive Disease Center (grant DK34988, National Institutes of Health, Bethesda, Maryland).
Rights and permissions
About this article
Cite this article
Talley, N.J., Phillips, S.F., Haddad, A. et al. GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Digest Dis Sci 35, 477–480 (1990). https://doi.org/10.1007/BF01536922
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01536922